

Highlights

1. Autoantibodies to neuronal proteins are promising biomarkers of neurodegenerative diseases
2. Mounting data suggests dissociation of autoantibody profiles and neurodegeneration in CNS
3. Autoantibody profiles may be influenced by neurodegeneration beyond CNS
4. Constitutive turnover of enteric neurons provides a continuous supply of neuronal antigens

1
2
3
4
5 **Perspective**
6
7

8
9
10 **Adult Neurogenesis in the Gut, Homeostatic Autoimmunity and Neurodegenerative**
11 **Disease Biomarkers**
12
13

14
15
16
17 **Author:** Saak V. Ovsepian¹ and Valerie B. O’Leary²
18
19

20
21
22 **Affiliation:** (1) Faculty of Science and Engineering, University of Greenwich London,
23 Chatham Maritime, Kent, ME4 4TB, United Kingdom; (2) Department of Medical Genetics,
24 Third Faculty of Medicine, Charles University, Ruská 87, 10000 Prague, Czechia.
25
26
27
28
29
30

31 **Correspondence:** Saak V. Ovsepian, Faculty of Science and Engineering, University of
32 Greenwich London, Chatham Maritime, Kent, ME4 4TB, United Kingdom.
33
34

35
36 Email: s.v.ovsepian@gre.ac.uk
37
38
39
40

41 **Conflict of interest:** The author reports no potential conflict of interest
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Autoantibodies to neuronal antigens are viewed as potential biomarkers for neurodegenerative diseases. Increasing evidence, however, suggests a dissociation of the neurodegenerative process in the central nervous system and dynamics of neuronal proteins in peripheral circulation with prevalence of a wide variety of immunoglobulins reactive to neuronal antigens reported also in the blood of healthy subjects, including children. Recently discovered physiological turnover of neurons in enteric nervous system with release of neuronal proteins in circulation may account for this conundrum and provide a new perspective on molecular biomarkers of neurodegenerative diseases and immunotherapy.

Highlights

1. Autoantibodies to neuronal proteins are promising biomarkers of neurodegenerative diseases
2. Mounting data suggests dissociation of autoantibody profiles and neurodegeneration in CNS
3. Autoantibody profiles may be influenced by neurodegeneration beyond CNS
4. Constitutive turnover of enteric neurons provides a continuous supply of neuronal antigens

Keywords

Adult neurogenesis; enteric nervous system; autoimmunity; neurodegenerative disease; tau; biomarkers

Abbreviations

NDD – neurodegenerative diseases; CSF – cerebrospinal fluid; Ig – immunoglobulins; Aab – autoantibodies; BBB – blood-brain barrier; CNS – central nervous system; AD – Alzheimer’s disease; NF – neurofilament; LB – Lewy bodies; PD – Parkinson’s disease.

Acknowledgements: Innovation Fund Award 2022 from the University of Greenwich; Charles University, Third Faculty of Medicine Research Program COOPERATIO-207036; Medical Diagnostics and Basic Medical Sciences in ‘Medical Genetics’.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Main

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Early detection of neurodegenerative diseases (NDDs) and targeted intervention are considered essential for successful future therapies. Although the slow progression of neuronal degeneration offers ample window for therapeutic intervention, at present, there are no rigorous methods for detecting pathological changes during the initial stages of the disease. Major efforts are underway toward developing sensitive methods for identifying subtle damage to brain tissue, based on alterations in neuronal proteins in cerebrospinal fluid (CSF) and peripheral circulation (Obrocki, Khatun et al. 2020, Zetterberg and Blennow 2021). A range of immunoassays has been designed using traditional detection methods and fluorescence-based techniques (proximity ligation assays, PLA), yielding higher sensitivity and multiplexing capacities (Obrocki, Khatun et al. 2020).

With the expanding portfolio of neuron-specific immunoglobulins (Ig) in biofluids of patients, the stakes are high for specific biomarkers of neuronal degeneration. It is generally assumed that during neurodegeneration, antigens released by injured neurons pass across the disrupted blood-brain barrier (BBB), inducing an immune response with production of specific autoantibodies (Aab). The rising evidence from clinical studies, while generally supportive of this premise, has challenged the expected correlation of Aab changes with the degenerative process in the central nervous system (CNS). Indeed, increasing data from Alzheimer's disease (AD) patients show the dissociation of the dynamics of anti-A β Ig in peripheral circulation from amyloid pathology in the brain (Kocurova, Ricny et al. 2022). Most A β 42 and A β 40 Aab studies, for instance, showed a lower titer of Ig in sera of patients compared to healthy groups, despite the flaring amyloid pathology in the brain (Du, Dodel et al. 2001, Qu, Gong et al. 2014, Lang and Pruss 2017, Kocurova, Ricny et al. 2022). The dissociation of Aab profiles in the blood from the neurodegenerative process in the CNS has been also reported for other neuronal markers, including microtubule-associated protein tau, axonal neurofilaments (NF) and α -

1 synuclein (Zetterberg and Burnham 2019, Gordon 2020, Kocurova, Riczny et al. 2022).
2 Notably, tau-reactive Aabs were found in immunoglobulin pools of large cohorts of healthy
3 subjects, including children (Kuhn, Rogosch et al. 2018, Kocurova, Riczny et al. 2022).
4
5 Moreover, some reports have shown a reduction of tau reactive Aabs in the serum of clinical
6
7 AD patients, as compared to healthy controls, with Ig concentration declining further with the
8
9 progression of the pathology (Bartos, Fialova et al. 2018, Kocurova, Riczny et al. 2022). Similar
10
11 to A β and tau Aabs, NF-reactive immunoglobins were also reported in the plasma of healthy
12
13 subjects (Kocurova, Riczny et al. 2022).
14
15
16
17
18

19 The abundance of immunoglobins reactive to neuronal antigens in healthy individuals
20
21 of different age groups advocates their possible physiological role. Although the significance
22
23 and mechanisms of the production of neuron-specific Aabs in healthy subjects remain to be
24
25 elucidated, one explanation for the deviation of the primary pathology in CNS and changes in
26
27 neuronal antigens in the periphery might be that the neurodegenerative process is not confined
28
29 to the brain and spinal cord but extends over the peripheral nervous system, which may not
30
31 strictly correlate with the pathology in the CNS. A detailed analysis of the distribution of Lewy
32
33 Bodies (LB) in patients affected by Parkinson's disease (PD), Lewy body dementia (LBD) and
34
35 AD, using phosphorylated α -synuclein assays have shown high densities proteinaceous
36
37 deposits in paraspinal sympathetic ganglia, vagus nerve, enteric plexus of the intestinal tract as
38
39 well as endocrine organs (Braak, de Vos et al. 2006, Beach, Adler et al. 2010, Natale, Pasquali
40
41 et al. 2011). Inclusions of α -synuclein were also found in parasympathetic preganglionic
42
43 projecting neurons of the dorsal motor nucleus of the vagus, sympathetic preganglionic
44
45 neurons, and post-ganglionic neurons of celiac ganglion (Braak, de Vos et al. 2006). Research
46
47 is currently underway elucidating the peripheral pathology with neuronal injury in NDDs, with
48
49 prion-like transmission to the lower brain stem nuclei and further up to forebrain structures.
50
51 While highly instructive for appreciation of the complexity of the pathobiology of NDDs, these
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 findings cannot explain the abundance of Aabs reactive to neuronal proteins in the peripheral
2 circulation of healthy subjects.
3

4
5 Recent studies of the enteric nervous system, which comprises the largest collection of
6
7 neurons outside of the CNS, have provided important clues that not only may explain the
8
9 dissociation between dynamics of neuron-specific Aabs in the blood and primary
10
11 neuropathology in the CNS but also can account for the presence of Aabs to neuronal injury
12
13 proteins in the circulation of healthy subjects. Despite the long-established view of the absence
14
15 of adult neurogenesis in the intestinal nervous system, the results of cytochemical and
16
17 immunofluorescence analysis of the enteric nervous system suggest a continuous proliferation
18
19 of neuronal progenitors with a supply of new neurons (Pham, Gershon et al. 1991, Laranjeira,
20
21 Sandgren et al. 2011, Kulkarni, Micci et al. 2017). This steady stream of fresh neurons ensures
22
23 the replacement of the rapidly degenerating old cells, keeping in check the neuronal population
24
25 of the intestine (Kulkarni, Micci et al. 2017). It was reported that at any given time, over 10 %
26
27 of myenteric neurons are positive for cleaved caspase 3, implying that they are on their way
28
29 out. With over 30% of these cells perishing within a week or so, the intense neuronal
30
31 disintegration in the intestinal wall mounts up to 4-5 % of neurons dying every day, releasing
32
33 large quantities of antigens in the circulation for disposal by the immune system (Kulkarni,
34
35 Micci et al. 2017). Given the critical role of the immune system in tissue homeostasis and
36
37 regeneration, the constitutive apoptosis of enteric neurons and the constant production of
38
39 endogenous antigens warrant a constant production and release of neuronal immunoglobins in
40
41 the peripheral circulation.
42
43
44
45
46
47
48
49

50
51 In summary, circulating in the blood Aabs targeting neuronal proteins, thus, emerge as
52
53 an important feature of homeostatic autoimmunity. With the onset of NDDs, it is conceivable
54
55 that part of the neuronal Aab portfolio acquires a new functionality - neutralizing neuronal
56
57 antigens released into circulation from the CNS. Although major gaps remain in understanding
58
59
60
61
62
63
64
65

1 the significance of homeostatic autoimmunity to neuronal proteins under physiological and
2 disease conditions, the outlined here model provides clues explaining the prevalence of
3 neuronal Aabs (and antigens) in healthy and NDDs subjects and offers a new conceptual
4 framework for making testable predictions in future studies. Filling the knowledge gaps in the
5 biology of neuronal autoimmunity should not only elucidate the highly complex and dynamic
6 relationship between the neurodegenerative process in the CNS and immune response but also
7 help to improve diagnostic assays and facilitate the development of effective immunotherapies.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Bartos, A., L. Fialova and J. Svarcova (2018). "Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease." J Alzheimers Dis **64**(3): 751-760.
- Beach, T. G., C. H. Adler, L. I. Sue, L. Vedders, L. Lue, C. L. White Iii, H. Akiyama, J. N. Caviness, H. A. Shill, M. N. Sabbagh, D. G. Walker and C. Arizona Parkinson's Disease (2010). "Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders." Acta Neuropathol **119**(6): 689-702.
- Braak, H., R. A. de Vos, J. Bohl and K. Del Tredici (2006). "Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology." Neurosci Lett **396**(1): 67-72.
- Du, Y., R. Dodel, H. Hampel, K. Buerger, S. Lin, B. Eastwood, K. Bales, F. Gao, H. J. Moeller, W. Oertel, M. Farlow and S. Paul (2001). "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease." Neurology **57**(5): 801-805.
- Gordon, B. A. (2020). "Neurofilaments in disease: what do we know?" Curr Opin Neurobiol **61**: 105-115.
- Kocurova, G., J. Riczny and S. V. Ovsepiyan (2022). "Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases." Theranostics **12**(7): 3045-3056.
- Kuhn, I., T. Rogosch, T. I. Schindler, B. Tackenberg, M. Zemlin, R. F. Maier, R. Dodel and Y. Kronimus (2018). "Serum titers of autoantibodies against alpha-synuclein and tau in child- and adulthood." J Neuroimmunol **315**: 33-39.
- Kulkarni, S., M. A. Micci, J. Leser, C. Shin, S. C. Tang, Y. Y. Fu, L. Liu, Q. Li, M. Saha, C. Li, G. Enikolopov, L. Becker, N. Rakhilin, M. Anderson, X. Shen, X. Dong, M. J. Butte, H. Song, E. M. Southard-Smith, R. P. Kapur, M. Bogunovic and P. J. Pasricha (2017). "Adult enteric nervous system in health is maintained by a dynamic balance between neuronal apoptosis and neurogenesis." Proc Natl Acad Sci U S A **114**(18): E3709-E3718.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Lang, K. and H. Pruss (2017). "Frequencies of neuronal autoantibodies in healthy controls: Estimation of disease specificity." Neurol Neuroimmunol Neuroinflamm **4**(5): e386.

Laranjeira, C., K. Sandgren, N. Kessar, W. Richardson, A. Potocnik, P. Vanden Berghe and V. Pachnis (2011). "Glial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury." J Clin Invest **121**(9): 3412-3424.

Natale, G., L. Pasquali, A. Paparelli and F. Fornai (2011). "Parallel manifestations of neuropathologies in the enteric and central nervous systems." Neurogastroenterol Motil **23**(12): 1056-1065.

Obrocki, P., A. Khatun, D. Ness, K. Senkevich, J. Hanrieder, F. Capraro, N. Mattsson, U. Andreasson, E. Portelius, N. J. Ashton, K. Blennow, M. Scholl, R. W. Paterson, J. M. Schott and H. Zetterberg (2020). "Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg." Alzheimers Res Ther **12**(1): 20.

Pham, T. D., M. D. Gershon and T. P. Rothman (1991). "Time of origin of neurons in the murine enteric nervous system: sequence in relation to phenotype." J Comp Neurol **314**(4): 789-798.

Qu, B. X., Y. Gong, C. Moore, M. Fu, D. C. German, L. Y. Chang, R. Rosenberg and R. Diaz-Arrastia (2014). "Beta-amyloid auto-antibodies are reduced in Alzheimer's disease." J Neuroimmunol **274**(1-2): 168-173.

Zetterberg, H. and K. Blennow (2021). "Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics." Mol Neurodegener **16**(1): 10.

Zetterberg, H. and S. C. Burnham (2019). "Blood-based molecular biomarkers for Alzheimer's disease." Mol Brain **12**(1): 26.

Figure 1

1
2 Schematic of the life journey of neurons in healthy ageing and neurodegenerative disease-
3
4 affected CNS (A), and in healthy intestinal nervous system (B). (A) In the course of
5
6 development, in CNS, neurons derived from neuronal progenitors mature (red arrows) and
7
8 progress through healthy ageing (blue arrows) or undergo neurodegeneration (grey arrows),
9
10 releasing neuronal antigens, i.e., β -amyloid, α -synuclein, MAP tau, NF etc., which leak in
11
12 peripheral circulation through injured blood-brain barriers (BBB, grey broken line), to
13
14 stimulate the production of natural autoantibodies (Aab). (B) In the intestinal nervous system,
15
16 on the other hand, there is an extensive physiological turnover of neurons, with dying nerve
17
18 cells constantly releasing antigens, i.e., β -amyloid, α -synuclein, MAP tau etc., into the blood
19
20 stream (across endothelium), activating homeostatic autoimmune response, which plays a key
21
22 role in integrity of intestinal functions.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

[Click here to view linked References](#)

1
2
3
4
5 **Perspective**
6
7

8
9
10 **Adult Neurogenesis in the Gut, Homeostatic Autoimmunity and Neurodegenerative**
11 **Disease Biomarkers**
12
13

14
15
16
17 **Author:** Saak V. Ovsepian¹ and Valerie B. O’Leary²
18
19

20
21
22 **Affiliation:** (1) Faculty of Science and Engineering, University of Greenwich London,
23 Chatham Maritime, Kent, ME4 4TB, United Kingdom; (2) Department of Medical Genetics,
24 Third Faculty of Medicine, Charles University, Ruská 87, 10000 Prague, Czechia.
25
26
27
28
29

30
31 **Correspondence:** Saak V. Ovsepian, Faculty of Science and Engineering, University of
32 Greenwich London, Chatham Maritime, Kent, ME4 4TB, United Kingdom.
33
34

35
36 Email: s.v.ovsepian@gre.ac.uk
37
38
39

40
41 **Conflict of interest:** The author reports no potential conflict of interest
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Autoantibodies to neuronal antigens are viewed as potential biomarkers for neurodegenerative diseases. Increasing evidence, however, suggests a dissociation of the neurodegenerative process in the central nervous system and dynamics of neuronal proteins in peripheral circulation with prevalence of a wide variety of immunoglobulins reactive to neuronal antigens reported also in the blood of healthy subjects, including children. Recently discovered physiological turnover of neurons in enteric nervous system with release of neuronal proteins in circulation may account for this conundrum and provide a new perspective on molecular biomarkers of neurodegenerative diseases and immunotherapy.

Highlights

1. Autoantibodies to neuronal proteins are promising biomarkers of neurodegenerative diseases
2. Mounting data suggests dissociation of autoantibody profiles and neurodegeneration in CNS
3. Autoantibody profiles may be influenced by neurodegeneration beyond CNS
4. Constitutive turnover of enteric neurons provides a continuous supply of neuronal antigens

Keywords

Adult neurogenesis; enteric nervous system; autoimmunity; neurodegenerative disease; tau; biomarkers

Abbreviations

NDD – neurodegenerative diseases; CSF – cerebrospinal fluid; Ig – immunoglobulins; Aab – autoantibodies; BBB – blood-brain barrier; CNS – central nervous system; AD – Alzheimer’s disease; NF – neurofilament; LB – Lewy bodies; PD – Parkinson’s disease.

Acknowledgements: Innovation Fund Award 2022 from the University of Greenwich; Charles University, Third Faculty of Medicine Research Program COOPERATIO-207036; Medical Diagnostics and Basic Medical Sciences in ‘Medical Genetics’.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Main

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Early detection of neurodegenerative diseases (NDDs) and targeted intervention are considered essential for successful future therapies. Although the slow progression of neuronal degeneration offers ample window for therapeutic intervention, at present, there are no rigorous methods for detecting pathological changes during the initial stages of the disease. Major efforts are underway toward developing sensitive methods for identifying subtle damage to brain tissue, based on alterations in neuronal proteins in cerebrospinal fluid (CSF) and peripheral circulation (Obrocki, Khatun et al. 2020, Zetterberg and Blennow 2021). A range of immunoassays has been designed using traditional detection methods and fluorescence-based techniques (proximity ligation assays, PLA), yielding higher sensitivity and multiplexing capacities (Obrocki, Khatun et al. 2020).

With the expanding portfolio of neuron-specific immunoglobulins (Ig) in biofluids of patients, the stakes are high for specific biomarkers of neuronal degeneration. It is generally assumed that during neurodegeneration, antigens released by injured neurons pass across the disrupted blood-brain barrier (BBB), inducing an immune response with production of specific autoantibodies (Aab). The rising evidence from clinical studies, while generally supportive of this premise, has challenged the expected correlation of Aab changes with the degenerative process in the central nervous system (CNS). Indeed, increasing data from Alzheimer's disease (AD) patients show the dissociation of the dynamics of anti-A β Ig in peripheral circulation from amyloid pathology in the brain (Kocurova, Ricny et al. 2022). Most A β 42 and A β 40 Aab studies, for instance, showed a lower titer of Ig in sera of patients compared to healthy groups, despite the flaring amyloid pathology in the brain (Du, Dodel et al. 2001, Qu, Gong et al. 2014, Lang and Pruss 2017, Kocurova, Ricny et al. 2022). The dissociation of Aab profiles in the blood from the neurodegenerative process in the CNS has been also reported for other neuronal markers, including microtubule-associated protein tau, axonal neurofilaments (NF) and α -

1 synuclein (Zetterberg and Burnham 2019, Gordon 2020, Kocurova, Riczny et al. 2022).
2 Notably, tau-reactive Aabs were found in immunoglobulin pools of large cohorts of healthy
3 subjects, including children (Kuhn, Rogosch et al. 2018, Kocurova, Riczny et al. 2022).
4
5 Moreover, some reports have shown a reduction of tau reactive Aabs in the serum of clinical
6
7 AD patients, as compared to healthy controls, with Ig concentration declining further with the
8
9 progression of the pathology (Bartos, Fialova et al. 2018, Kocurova, Riczny et al. 2022). Similar
10
11 to A β and tau Aabs, NF-reactive immunoglobins were also reported in the plasma of healthy
12
13 subjects (Kocurova, Riczny et al. 2022).
14
15
16
17
18

19 The abundance of immunoglobins reactive to neuronal antigens in healthy individuals
20
21 of different age groups advocates their possible physiological role. Although the significance
22
23 and mechanisms of the production of neuron-specific Aabs in healthy subjects remain to be
24
25 elucidated, one explanation for the deviation of the primary pathology in CNS and changes in
26
27 neuronal antigens in the periphery might be that the neurodegenerative process is not confined
28
29 to the brain and spinal cord but extends over the peripheral nervous system, which may not
30
31 strictly correlate with the pathology in the CNS. A detailed analysis of the distribution of Lewy
32
33 Bodies (LB) in patients affected by Parkinson's disease (PD), Lewy body dementia (LBD) and
34
35 AD, using phosphorylated α -synuclein assays have shown high densities proteinaceous
36
37 deposits in paraspinal sympathetic ganglia, vagus nerve, enteric plexus of the intestinal tract as
38
39 well as endocrine organs (Braak, de Vos et al. 2006, Beach, Adler et al. 2010, Natale, Pasquali
40
41 et al. 2011). Inclusions of α -synuclein were also found in parasympathetic preganglionic
42
43 projecting neurons of the dorsal motor nucleus of the vagus, sympathetic preganglionic
44
45 neurons, and post-ganglionic neurons of celiac ganglion (Braak, de Vos et al. 2006). Research
46
47 is currently underway elucidating the peripheral pathology with neuronal injury in NDDs, with
48
49 prion-like transmission to the lower brain stem nuclei and further up to forebrain structures.
50
51 While highly instructive for appreciation of the complexity of the pathobiology of NDDs, these
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 findings cannot explain the abundance of Aabs reactive to neuronal proteins in the peripheral
2 circulation of healthy subjects.
3

4
5 Recent studies of the enteric nervous system, which comprises the largest collection of
6
7 neurons outside of the CNS, have provided important clues that not only may explain the
8
9 dissociation between dynamics of neuron-specific Aabs in the blood and primary
10
11 neuropathology in the CNS but also can account for the presence of Aabs to neuronal injury
12
13 proteins in the circulation of healthy subjects. Despite the long-established view of the absence
14
15 of adult neurogenesis in the intestinal nervous system, the results of cytochemical and
16
17 immunofluorescence analysis of the enteric nervous system suggest a continuous proliferation
18
19 of neuronal progenitors with a supply of new neurons (Pham, Gershon et al. 1991, Laranjeira,
20
21 Sandgren et al. 2011, Kulkarni, Micci et al. 2017). This steady stream of fresh neurons ensures
22
23 the replacement of the rapidly degenerating old cells, keeping in check the neuronal population
24
25 of the intestine (Kulkarni, Micci et al. 2017). It was reported that at any given time, over 10 %
26
27 of myenteric neurons are positive for cleaved caspase 3, implying that they are on their way
28
29 out. With over 30% of these cells perishing within a week or so, the intense neuronal
30
31 disintegration in the intestinal wall mounts up to 4-5 % of neurons dying every day, releasing
32
33 large quantities of antigens in the circulation for disposal by the immune system (Kulkarni,
34
35 Micci et al. 2017). Given the critical role of the immune system in tissue homeostasis and
36
37 regeneration, the constitutive apoptosis of enteric neurons and the constant production of
38
39 endogenous antigens warrant a constant production and release of neuronal immunoglobins in
40
41 the peripheral circulation.
42
43
44
45
46
47
48
49

50
51 In summary, circulating in the blood Aabs targeting neuronal proteins, thus, emerge as
52
53 an important feature of homeostatic autoimmunity. With the onset of NDDs, it is conceivable
54
55 that part of the neuronal Aab portfolio acquires a new functionality - neutralizing neuronal
56
57 antigens released into circulation from the CNS. Although major gaps remain in understanding
58
59
60
61
62
63
64
65

1 the significance of homeostatic autoimmunity to neuronal proteins under physiological and
2 disease conditions, the outlined here model provides clues explaining the prevalence of
3 neuronal Aabs (and antigens) in healthy and NDDs subjects and offers a new conceptual
4 framework for making testable predictions in future studies. Filling the knowledge gaps in the
5 biology of neuronal autoimmunity should not only elucidate the highly complex and dynamic
6 relationship between the neurodegenerative process in the CNS and immune response but also
7 help to improve diagnostic assays and facilitate the development of effective immunotherapies.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Bartos, A., L. Fialova and J. Svarcova (2018). "Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease." J Alzheimers Dis **64**(3): 751-760.
- Beach, T. G., C. H. Adler, L. I. Sue, L. Vedders, L. Lue, C. L. White Iii, H. Akiyama, J. N. Caviness, H. A. Shill, M. N. Sabbagh, D. G. Walker and C. Arizona Parkinson's Disease (2010). "Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders." Acta Neuropathol **119**(6): 689-702.
- Braak, H., R. A. de Vos, J. Bohl and K. Del Tredici (2006). "Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology." Neurosci Lett **396**(1): 67-72.
- Du, Y., R. Dodel, H. Hampel, K. Buerger, S. Lin, B. Eastwood, K. Bales, F. Gao, H. J. Moeller, W. Oertel, M. Farlow and S. Paul (2001). "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease." Neurology **57**(5): 801-805.
- Gordon, B. A. (2020). "Neurofilaments in disease: what do we know?" Curr Opin Neurobiol **61**: 105-115.
- Kocurova, G., J. Riczny and S. V. Ovsepiyan (2022). "Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases." Theranostics **12**(7): 3045-3056.
- Kuhn, I., T. Rogosch, T. I. Schindler, B. Tackenberg, M. Zemlin, R. F. Maier, R. Dodel and Y. Kronimus (2018). "Serum titers of autoantibodies against alpha-synuclein and tau in child- and adulthood." J Neuroimmunol **315**: 33-39.
- Kulkarni, S., M. A. Micci, J. Leser, C. Shin, S. C. Tang, Y. Y. Fu, L. Liu, Q. Li, M. Saha, C. Li, G. Enikolopov, L. Becker, N. Rakhilin, M. Anderson, X. Shen, X. Dong, M. J. Butte, H. Song, E. M. Southard-Smith, R. P. Kapur, M. Bogunovic and P. J. Pasricha (2017). "Adult enteric nervous system in health is maintained by a dynamic balance between neuronal apoptosis and neurogenesis." Proc Natl Acad Sci U S A **114**(18): E3709-E3718.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Lang, K. and H. Pruss (2017). "Frequencies of neuronal autoantibodies in healthy controls: Estimation of disease specificity." Neurol Neuroimmunol Neuroinflamm **4**(5): e386.

Laranjeira, C., K. Sandgren, N. Kessar, W. Richardson, A. Potocnik, P. Vanden Berghe and V. Pachnis (2011). "Glial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury." J Clin Invest **121**(9): 3412-3424.

Natale, G., L. Pasquali, A. Paparelli and F. Fornai (2011). "Parallel manifestations of neuropathologies in the enteric and central nervous systems." Neurogastroenterol Motil **23**(12): 1056-1065.

Obrocki, P., A. Khatun, D. Ness, K. Senkevich, J. Hanrieder, F. Capraro, N. Mattsson, U. Andreasson, E. Portelius, N. J. Ashton, K. Blennow, M. Scholl, R. W. Paterson, J. M. Schott and H. Zetterberg (2020). "Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg." Alzheimers Res Ther **12**(1): 20.

Pham, T. D., M. D. Gershon and T. P. Rothman (1991). "Time of origin of neurons in the murine enteric nervous system: sequence in relation to phenotype." J Comp Neurol **314**(4): 789-798.

Qu, B. X., Y. Gong, C. Moore, M. Fu, D. C. German, L. Y. Chang, R. Rosenberg and R. Diaz-Arrastia (2014). "Beta-amyloid auto-antibodies are reduced in Alzheimer's disease." J Neuroimmunol **274**(1-2): 168-173.

Zetterberg, H. and K. Blennow (2021). "Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics." Mol Neurodegener **16**(1): 10.

Zetterberg, H. and S. C. Burnham (2019). "Blood-based molecular biomarkers for Alzheimer's disease." Mol Brain **12**(1): 26.

Figure 1

1
2 Schematic of the life journey of neurons in healthy ageing and neurodegenerative disease-
3
4 affected CNS (A), and in healthy intestinal nervous system (B). (A) In the course of
5
6 development, in CNS, neurons derived from neuronal progenitors mature (red arrows) and
7
8 progress through healthy ageing (blue arrows) or undergo neurodegeneration (grey arrows),
9
10 releasing neuronal antigens, i.e., β -amyloid, α -synuclein, MAP tau, NF etc., which leak in
11
12 peripheral circulation through injured blood-brain barriers (BBB, grey broken line), to
13
14 stimulate the production of natural autoantibodies (Aab). (B) In the intestinal nervous system,
15
16 on the other hand, there is an extensive physiological turnover of neurons, with dying nerve
17
18 cells constantly releasing antigens, i.e., β -amyloid, α -synuclein, MAP tau etc., into the blood
19
20 stream (across endothelium), activating homeostatic autoimmune response, which plays a key
21
22 role in integrity of intestinal functions.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

